Sign in →

Test ID: CCMGG Comprehensive Cardiomyopathy Gene Panel, Varies


Ordering Guidance


Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH/ Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

 

Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.



Shipping Instructions


Specimen preferred to arrive within 96 hours of collection.



Necessary Information


Prior Authorization is available, but not required, for this test. If proceeding with the prior authorization process, submit the required form with the specimen.



Specimen Required


Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred)/Refrigerated


Forms

1. New York Clients-Informed consent is required.

Document on the request form or electronic order that a copy is on file.

The following documents are available:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

2. Hereditary Cardiomyopathies and Arrhythmias Patient Information

3. Comprehensive Cardiomyopathy Panel (CCMGG) Prior Authorization Ordering Instructions

4. If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.

Useful For

Providing a genetic evaluation for patients with a personal or family history suggestive of a hereditary form of cardiomyopathy

 

Establishing a diagnosis of a hereditary form of cardiomyopathy

Method Name

Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing.

Reporting Name

Comprehensive Cardiomyopathy Panel

Specimen Type

Varies

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Clinical Information

Cardiomyopathies are a group of disorders characterized by disease of the heart muscle. Cardiomyopathy can be caused by either inherited, genetic factors or nongenetic (acquired) causes, such as infection or trauma. When the presence or severity of the cardiomyopathy observed in a patient cannot be explained by acquired causes, genetic testing for the inherited forms of cardiomyopathy may be considered. Overall, cardiomyopathies are some of the most common genetic disorders. The inherited forms of cardiomyopathy include hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC or AC), and left ventricular noncompaction (LVNC).(1)

 

The hereditary form of HCM is characterized by left ventricular hypertrophy in the absence of other cardiac or systemic causes that may cause hypertrophy of the heart muscle, such as longstanding, uncontrolled hypertension or aortic stenosis. The incidence of HCM in the general population is approximately 1:200 to 1:500, and it is estimated that 30% to 60% of cases can be attributed to a genetic etiology.(2) Hereditary forms of HCM are most often caused by genes encoding proteins of the cardiac sarcomere, the functional contractile unit of the heart muscle.

 

Hereditary forms of DCM are characterized by ventricular dilation with reduced cardiac performance in the absence of other cardiac or systemic causes that may cause dilation of the heart muscle, such as hypertension and ischemic heart disease. The incidence of DCM in the general population is approximately 1 in 2500, and it is estimated that approximately 50% of cases can be attributed to a genetic etiology.(3) Hereditary forms of DCM are most often caused by genes encoding proteins of the cardiac cytoskeleton and sarcomere.

 

LVNC is characterized by prominent trabeculations of the left ventricle with trabecular recesses extending into the ventricular cavity. The incidence of LVNC in the general population is estimated to be 1 in 5000.(3) It is currently unclear if LVNC represents a genetically distinct form of cardiomyopathy, as many familial cases of LVNC have been linked to the same genes associated with other forms of hereditary cardiomyopathies and many affected individuals also meet diagnostic criteria for DCM or HCM.(3,4)

 

Arrhythmogenic cardiomyopathy (ACM) is characterized by the presence of arrhythmogenic cardiac muscle in the absence of ischemic, hypertensive, or valvular cardiac disease. ARVC, the most well-defined form of ACM, is characterized by the breakdown of the myocardium and replacement of right ventricular muscle tissue with fibrofatty tissue, resulting in an increased risk of arrhythmia and sudden death. In some cases, there may also be left ventricular involvement. The prevalence of ARVC (genetic and acquired) is estimated to be 1 in 2000 to 1 in 5000 in the general population.(5)

 

Hereditary forms of cardiomyopathy may be an isolated finding or may be a feature of an underlying systemic condition. Hereditary forms of cardiomyopathy can follow autosomal dominant, autosomal recessive, X-linked, and digenic patterns of inheritance. Mitochondrial inheritance is also possible, however, genes associated with mitochondrial inheritance of cardiomyopathy are not assessed on this panel.

Reference Values

An interpretive report will be provided.

Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(6) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Clinical Reference

1. Hershberger RE, Givertz MM, Ho CY, et al: Genetic evaluation of cardiomyopathy-a heart failure society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi: 10.1016/j.cardfail.2018.03.004

2. Ommen SR, Mital S, Burke MA, et al: 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive Summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2020;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938

3. Bozkurt B, Colvin M, Cook J, et al: Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association [published correction appears in Circulation. 2016 Dec 6;134(23 ):e652]. Circulation. 2016;134(23):e579-e646. doi: 10.1161/CIR.0000000000000455

4. Aung N, Doimo S, Ricci F, et al: Prognostic significance of left ventricular noncompaction: Systematic review and meta-analysis of observational studies. Circ Cardiovasc Imaging. 2020 Jan;13(1):e009712. doi: 10.1161/CIRCIMAGING.119.009712

5. Corrado D, Link MS, Calkins H: Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017 Jan;376(1):61-72. doi: 10.1056/NEJMra1509267

6. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015 May;17(5):405-424. doi: 10.1038/gim.2015.30

Day(s) Performed

Varies

Report Available

28 to 42 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81439

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CCMGG Comprehensive Cardiomyopathy Panel 51966-0

 

Result ID Test Result Name Result LOINC Value
617184 Test Description 62364-5
617185 Specimen 31208-2
617186 Source 31208-2
617187 Result Summary 50397-9
617188 Result 82939-0
617189 Interpretation 69047-9
617190 Additional Results 82939-0
617191 Resources 99622-3
617192 Additional Information 48767-8
617193 Method 85069-3
617194 Genes Analyzed 48018-6
617195 Disclaimer 62364-5
617196 Released By 18771-6
Mayo Clinic Laboratories | Cardiology Catalog Additional Information:

multi-gene panel